QBS10072S

DRUG2 trials

Sponsors

David Reardon, MD, Quadriga Biosciences, Inc.

Conditions

AstrocytomaBladder CancerBrain CancerBrain MetastasesBreast CancerCervical CancerCholangiocarcinomaColorectal Cancer

Phase 1

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

CompletedNCT04430842

Quadriga Biosciences, Inc.Astrocytoma, Bladder Cancer, Brain Cancer +20

Start: 2020-07-20End: 2022-12-22Updated: 2023-01-18

Phase 2

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

RecruitingNCT02977780

David Reardon, MDGlioblastoma

Start: 2017-02-09End: 2028-04-30Target: 460Updated: 2026-08-19

Related Papers

Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data

Journal of Clinical Oncology2026-05-22

CTNI-73. LAT1 EXPRESSION SCALE AND ADAPTIVE DESIGN FOR A PHASE IIA TRIAL OF QBS72S IN BREAST CANCER BRAIN METASTASES

Neuro-Oncology2025-11-01

Adaptive cohort design and LAT1 expression scale: study protocol for a Phase 2a trial of QBS72S in breast cancer brain metastases

BMC Cancer2025-08-151 citations

CTNI-60. SAFETY LEAD-IN RESULTS FOR QBS10072S IN THE INDIVIDUAL SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT) TRIAL, A RANDOMIZED ADAPTIVE PLATFORM TRIAL FOR NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA

Neuro-Oncology2024-11-011 citations

CTNI-17. APPLICATION OF THE GBM-X DATA PLATFORM TO ESTIMATE TREATMENT EFFECTS OF THE EXPERIMENTAL THERAPIES OF THE RANDOMIZED PHASE 2 INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPIES

Neuro-Oncology2023-11-01

Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization

Journal of Clinical Oncology2023-09-1838 citations

Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system

Neuro-Oncology Advances2023-01-0117 citations

Feasibility and conduct of INSIGhT, a platform trial of patients with glioblastoma using Bayesian adaptive randomization.

Journal of Clinical Oncology2022-06-012 citations

Preliminary results of the abemaciclib arm in the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A phase II platform trial using Bayesian adaptive randomization.

Journal of Clinical Oncology2021-05-2018 citations

Evaluating the benefit of adaptive randomization in the CC-115 arm of the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A phase II randomized Bayesian adaptive platform trial in newly diagnosed MGMT unmethylated glioblastoma.

Journal of Clinical Oncology2021-05-207 citations

<p>First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy</p>

Cancer Management and Research2019-12-0179 citations

Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma

JCO Precision Oncology2019-03-2775 citations

INNV-13. ALLELE: A CONSORTIUM FOR PROSPECTIVE GENOMICS AND FUNCTIONAL DIAGNOSTICS TO GUIDE PATIENT CARE AND TRIAL ANALYSIS IN NEWLY-DIAGNOSED GLIOBLASTOMA

Neuro-Oncology2018-11-01

ALLELE: A consortium for prospective genomics and functional diagnostics to guide patient care and trial analysis in newly-diagnosed glioblastoma.

Journal of Clinical Oncology2018-05-201 citations

Individualized screening trial of innovative glioblastoma therapy (INSIGhT).

Journal of Clinical Oncology2017-05-2016 citations